St. Louis biotech startup C2N Diagnostics joins pharma giants Lilly, Merck in 'pioneering' Alzheimer's disease study

St. Louis Business Journal

May 12, 2021

C2N Diagnostics is one of several partner organizations in the Bio-Hermes Study, a clinical trial being conducted to compare biomarker tests for Alzheimer's disease.